Literature DB >> 6759081

C-peptide.

J B Hoekstra, H J van Rijn, D W Erkelens, J H Thijssen.   

Abstract

C-peptide is a polypeptide originating from proinsulin after its cleavage in the B-cell. It is secreted equimolarly with the other cleavage product, insulin, into the portal circulation. Only a minimal fraction of C-peptide is extracted by the liver; it is supposed to be mainly removed by the kidney. A small, constant proportion is excreted in the urine. C-peptide is measured in serum and urine by radioimmunoassay. The major sources of error of the assay are related to standard, tracer, antiserum specificity and reactivity with proinsulin, and to degradation of C-peptide. Many secretagogues are used to evaluate the B-cell function, of which glucagon is the most simple. Clinical applications of C-peptide include differentiating between endogenous and exogenous hyperinsulinism and establishing the need of insulin therapy in diabetic patients already treated with insulin. The primary value of C-peptide, however, is in clinical research, where it offers a unique opportunity to follow the B-cell secretion in diabetic subjects and to evaluate the difference that various factors may exert on its activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759081     DOI: 10.2337/diacare.5.4.438

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Residual B-cell function in insulin-dependent (type I) diabetics with and without retinopathy.

Authors:  P Sberna; U Valentini; A Cimino; M C Sabatti; A Rotondi; M Crisetig; S Spandrio
Journal:  Acta Diabetol Lat       Date:  1986 Oct-Dec

2.  Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey.

Authors:  P A Gruppuso; J B Susa; P Sehgal; B Frank; R Schwartz
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Further evidence that insulin metabolism is a major determinant of peripheral insulin response to oral glucose in subjects with mild glucose intolerance.

Authors:  E Bonora; I Zavaroni; V Manicardi; C Coscelli; U Butturini
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

4.  Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

Authors:  K S Polonsky; J Licinio-Paixao; B D Given; W Pugh; P Rue; J Galloway; T Karrison; B Frank
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

5.  Glycosylated haemoglobin and glucose intolerance in cystic fibrosis.

Authors:  P R Stutchfield; S O'Halloran; J D Teale; D Isherwood; C S Smith; D Heaf
Journal:  Arch Dis Child       Date:  1987-08       Impact factor: 3.791

6.  Fractional hepatic extraction of insulin in man: is it constant?

Authors:  E Bonora; L Capretti; V Manicardi; I Zavaroni; C Coscelli; U Butturini
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

7.  Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.

Authors:  Jean-Patrice Baillargeon; André Carpentier
Journal:  Fertil Steril       Date:  2007-06-07       Impact factor: 7.329

8.  Treatment of diabetes with insulin. From art to science.

Authors:  M C Riddle
Journal:  West J Med       Date:  1983-06

9.  Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation to clinical and metabolic features.

Authors:  E Bonora; C Coscelli; U Butturini
Journal:  Acta Diabetol Lat       Date:  1984 Oct-Dec

10.  Impact of Chronic Periodontitis on Levels of Glucoregulatory Biomarkers in Gingival Crevicular Fluid of Adults with and without Type 2 Diabetes.

Authors:  Hasaan G Mohamed; Shaza B Idris; Manal Mustafa; Mutaz F Ahmed; Anne N Åstrøm; Kamal Mustafa; Salah O Ibrahim
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.